- Home
- AXP vs AZN Comparison
AXP vs AZN Comparison
Compare AXP & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXP
- AZN
- Stock Information
- Founded
- AXP 1850
- AZN 1992
- Country
- AXP United States
- AZN United Kingdom
- Employees
- AXP N/A
- AZN N/A
- Industry
- AXP Finance: Consumer Services
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- AXP Finance
- AZN Health Care
- Exchange
- AXP Nasdaq
- AZN Nasdaq
- Market Cap
- AXP 218.5B
- AZN 205.5B
- IPO Year
- AXP N/A
- AZN 1993
- Fundamental
- Price
- AXP $283.67
- AZN $67.30
- Analyst Decision
- AXP Hold
- AZN Strong Buy
- Analyst Count
- AXP 21
- AZN 5
- Target Price
- AXP $292.60
- AZN $92.33
- AVG Volume (30 Days)
- AXP 3.1M
- AZN 5.3M
- Earning Date
- AXP 04-17-2025
- AZN 04-29-2025
- Dividend Yield
- AXP 1.16%
- AZN 2.29%
- EPS Growth
- AXP 17.98
- AZN 22.71
- EPS
- AXP 14.32
- AZN 4.97
- Revenue
- AXP $62,049,000,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- AXP $18.59
- AZN $9.27
- Revenue Next Year
- AXP $8.09
- AZN $6.02
- P/E Ratio
- AXP $19.81
- AZN $13.54
- Revenue Growth
- AXP 9.05
- AZN 15.48
- 52 Week Low
- AXP $220.43
- AZN $61.24
- 52 Week High
- AXP $326.27
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- AXP 62.86
- AZN 40.16
- Support Level
- AXP $273.61
- AZN $69.70
- Resistance Level
- AXP $281.59
- AZN $72.69
- Average True Range (ATR)
- AXP 7.13
- AZN 1.31
- MACD
- AXP 3.13
- AZN 0.14
- Stochastic Oscillator
- AXP 96.04
- AZN 11.64
About AXP American Express Company
American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. Since 2018, it has operated in three segments: global consumer services, global commercial services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.